Form 8-K · Current report
Danaher Corporation 8-K, filed Oct 21, 2026
- Filed
- CIK
- 0000313616
- Accession no.
- 0000313616-26-000201
Summary
Danaher reported third-quarter 2026 net earnings of $1.2 billion, or $1.71 per diluted share, up 34.5% year over year, on revenue of $6.6 billion, up 8.5%, and raised its full-year adjusted diluted EPS guidance to $8.57–$8.62 from $8.45–$8.60. CEO Julie Sawyer Montgomery said revenue, earnings and cash flow came in better than expected, with core revenue growth excluding respiratory revenue continuing to accelerate.
Key points
- Revenue rose 8.5% year over year to $6.6 billion; non-GAAP core revenue grew 3.0%, or 5.5% excluding respiratory revenue.
- Non-GAAP adjusted diluted EPS rose 11.5% to $2.11; operating cash flow was $1.9 billion and non-GAAP free cash flow $1.6 billion.
- Fourth-quarter non-GAAP core revenue excluding respiratory revenue is expected to grow 4.0% to 5.0% year over year, with respiratory revenue an approximately 150 basis point headwind, implying core growth of about 3.0%.
- Full-year 2026 adjusted diluted EPS guidance was increased to $8.57–$8.62.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION On October 21, 2026, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the quarter ended September 25, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Danaher pursuant to Item 2.02 of Form 8-K. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.